All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Completed, but no date, and reported results | 2004-000462-13 | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting... | bad-data | |
| Completed, but no date, and reported results | 2004-000463-94 | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting... | bad-data | |
| Reported results | 2004-000759-40 | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. | 2006-06-28 | due-trials |
| Reported results | 2004-000762-13 | A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. ... | 2006-01-03 | due-trials |
| Reported results | 2004-003943-28 | A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in re... | 2006-06-28 | due-trials |
| Reported results | 2004-004612-23 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Designed, Escalating Dose Study to Assess the Tolerability, Safety and Maximal Tolerated Dose MTD of Ladostigil in Pat... | 2007-03-05 | due-trials |
| Completed, but no date | 2004-004901-12 | Phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU Versus the Classical Sequential administration of Leucovorin Calcium followed by 5-FU both in combination with standard Iri... | bad-data | |
| Reported results | 2005-001391-12 | A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 f... | 2007-02-28 | due-trials |
| Reported results | 2005-001416-42 | A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects | 2008-11-27 | due-trials |
| Reported results | 2005-004334-41 | An active extension of LAQ/5062 study. A multinational, multi-center, randomized, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3mg and 0.6mg) o... | 2017-07-23 | due-trials |
| Reported results | 2006-001688-49 | A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate for Injection in Subjects w... | 2008-06-17 | due-trials |
| Reported results | 2006-002037-20 | A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind, Study, to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate I... | 2019-07-21 | due-trials |
| Reported results | 2006-005140-89 | A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJ... | 2008-02-11 | due-trials |
| Reported results | 2007-003226-19 | A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in... | 2010-11-08 | due-trials |
| Reported results | 2007-005450-23 | A Multinational, Multicenter, Randomized, Parallel-Group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod ov... | 2011-06-29 | due-trials |
| Reported results | 2007-007455-14 | A single-centre, open-label, randomised, 2-way cross-over study to determine the effects on the short-term lower leg growth rate between Qvar® 100 μg bd delivered via a metered dose inhaler (MDI) (TEV... | 2008-12-18 | due-trials |
| Reported results | 2008-000709-12 | Estudio prospectivo, abierto, aleatorizado del tratamiento de combinación de MYOCET® más ciclofosfamida y trastuzumab frente a doxorubicina libre más ciclofosfamida sola, seguidos cada uno de docetaxe... | 2016-02-22 | due-trials |
| Reported results | 2008-002062-62 | A Multinational, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sc... | 2010-07-19 | due-trials |
| Reported results | 2008-004276-49 | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laq... | 2011-11-24 | due-trials |
| Reported results | 2009-010562-31 | Comparative bioavailability of Myfenax® (Teva) and CellCept® (Roche) in stable patients after renal transplantation | 2010-10-18 | due-trials |
| Reported results | 2009-011541-24 | An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study | 2013-02-28 | due-trials |
| Reported results | 2009-012989-30 | A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laqui... | 2017-05-09 | due-trials |
| Reported results | 2009-014644-11 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of t... | 2011-10-19 | due-trials |
| Reported results Terminated | 2009-015815-42 | A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquini... | 2017-05-09 | due-trials |
| Reported results | 2009-018084-27 | A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Ac... | 2017-05-12 | due-trials |
| Reported results | 2010-018329-20 | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination ... | 2012-10-24 | due-trials |
| Reported results | 2010-019001-42 | A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim i... | 2012-02-23 | due-trials |
| Completed, but no date, and reported results | 2010-019082-29 | A double-blind, double-dummy, randomized, placebo- and active-controlled, three-way crossover study to evaluate the effect of Budesonide/Formoterol Spiromax® 80/4.5 mcg Inhalation Powder and Symbicort... | bad-data | |
| Reported results | 2010-021011-16 | A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer | 2014-06-30 | due-trials |
| Reported results | 2010-023215-34 | A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-day Extended Cycle Oral Contraceptive Regimen, Compared to two 28-day Standard Oral Contraceptive Regimens, ... | 2011-12-02 | due-trials |
| Reported results | 2010-023342-67 | A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) with E... | 2013-09-12 | due-trials |
| Reported results | 2010-023600-27 | A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subje... | 2013-07-10 | due-trials |
| Reported results | 2010-023601-35 | A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Orally Twice Daily compared with Placebo in Adolescent and Adul... | 2013-10-10 | due-trials |
| Reported results | 2010-024006-35 | A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75 ye... | 2014-04-03 | due-trials |
| Reported results | 2010-024150-10 | A 15-week, double-blind, randomized, active-controlled, multicenter study to evaluate the efficiency and safety of Alendronate plus Vitamin D3 in the prevention of Vitamin D3 insufficiency and deficie... | 2012-08-02 | due-trials |
| Reported results | 2010-024540-15 | An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Study ... | 2015-01-16 | due-trials |
| Reported results | 2010-024614-66 | A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations and Change in Lung Fu... | 2014-03-04 | due-trials |
| Reported results | 2011-002602-78 | A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women | 2012-09-06 | due-trials |
| Reported results | 2011-004742-18 | Multicenter, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100μg/kg XM22 in 21 Children with E... | 2015-04-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-005021-48 | A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability and pharmacodynamic profiles of TL011 infusions compared with MabThera® ... | 2012-08-01 | bad-data |
| Reported results Terminated | 2011-005550-57 | A multinational, multicenter, randomized, parallel group, double blind, placebo controlled study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety... | 2012-08-06 | due-trials |
| Reported results | 2012-001107-20 | A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b) | 2014-04-09 | due-trials |
| Reported results Terminated | 2012-001818-42 | A Double-blind, Randomized, Sham?procedure?controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due ... | 2016-08-02 | due-trials |
| Reported results | 2012-002447-14 | A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV- 1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastati... | 2016-11-17 | due-trials |
| Reported results | 2012-003413-33 | A Randomized, Open-Label, Repeat Dosing (7 days), Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered via Breath Actuated Inhaler (BAI), S... | 2013-07-04 | due-trials |
| Reported results | 2012-003647-30 | A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two dose... | 2017-07-04 | due-trials |
| Reported results | 2012-004975-37 | A 64-Week (12-week core phase and 52-week safety extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults with Grow... | 2015-06-22 | due-trials |
| Reported results | 2012-005432-28 | An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 μg/kg and 670 μg/kg in pediatric... | 2014-11-13 | due-trials |
| Reported results | 2013-000081-11 | A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthm... | 2014-03-20 | due-trials |
| Completed, but no date, and reported results | 2013-000208-41 | A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/week or 300 m... | bad-data | |
| Reported results | 2013-001284-23 | A randomized, phase IIIB, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta®, Amgen) in elderly pat... | 2018-04-24 | due-trials |
| Reported results | 2013-001888-23 | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Pl... | 2016-07-08 | due-trials |
| Reported results Terminated | 2013-002082-19 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of L... | 2014-02-19 | due-trials |
| Reported results | 2013-003397-27 | A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety Of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered vi... | 2014-11-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-004468-69 | A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone (Genotropin®) Therapy in Treatment-Naive, Pre-... | 2016-04-29 | bad-data |
| Reported results | 2013-004630-14 | A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) Spiromax(160/4.5 and 320/9 mcg) as Compared to SYMBICORT® TURBOHALER... | 2015-03-13 | due-trials |
| Reported results | 2013-004632-30 | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via... | 2016-02-11 | due-trials |
| Reported results | 2014-000418-75 | A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients wi... | 2018-06-19 | due-trials |
| Reported results | 2014-000923-25 | A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler in A... | 2015-09-26 | due-trials |
| Reported results | 2014-001149-25 | A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler in A... | 2015-09-21 | due-trials |
| Reported results | 2014-001579-30 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6... | 2017-10-01 | due-trials |
| Reported results | 2014-001772-55 | A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 μg/kg tbo-filgrastim in... | 2017-04-03 | due-trials |
| Reported results | 2014-002659-25 | An Open-Label Safety Study of Patients with Severe Eosinophilic Asthma Who Were Previously Enrolled in the Reslizumab Open Label Extension Study C38072/3085 | 2017-03-06 | due-trials |
| Reported results | 2014-002736-13 | A phase 3, multicenter, randomized, open-label, comparator-controlled study to assess safety and tolerability of weekly TV-1106 compared to daily rhGH (Genotropin®) in adults with growth hormone-defic... | 2015-12-18 | due-trials |
| Reported results | 2014-003796-32 | A phase 3, multicenter, randomized, double-blind, placebo-controlled efficacy, safety and tolerability study of TV-1106 in growth hormone-deficient adults who are not current users of rhGH treatment | 2015-12-28 | due-trials |
| Reported results | 2014-005096-85 | Safety and Efficacy of LONQUEX® (Lipegfilgrastim) in Comparison to Pegfilgrastim (Neulasta®, Amgen Inc.) and Placebo in Patients with Non-Small-Cell Lung Cancer Receiving First-Line Chemotherapy | 2018-02-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-000087-34 | An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 μg/kg Body... | 2019-01-08 | bad-data |
| Reported results | 2015-000865-29 | A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils | 2018-01-31 | due-trials |
| Reported results | 2015-000904-24 | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease Studio multicentrico in aperto finalizzato alla valutazione d... | 2018-01-12 | due-trials |
| Reported results | 2015-000922-12 | A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous In... | 2017-06-02 | due-trials |
| Reported results | 2015-001580-39 | A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 weeks) in Patients with Oral Corticosteroid Dependent A... | 2017-12-04 | due-trials |
| Reported results | 2015-004549-23 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for th... | 2017-04-11 | due-trials |
| Reported results | 2015-004550-18 | A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV 48125 for the Preventive Treatment of Mi... | 2018-12-07 | due-trials |
| Reported results | 2015-004598-34 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for th... | 2017-04-11 | due-trials |
| Reported results | 2016-000622-19 | A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents | 2019-11-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-000630-22 | An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and ... | 2020-05-15 | bad-data |
| Reported results Terminated | 2016-003171-21 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-... | 2018-06-15 | due-trials |
| Reported results | 2016-003172-43 | A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache | 2019-06-11 | due-trials |
| Reported results | 2016-003278-42 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-... | 2019-04-23 | due-trials |
| Reported results | 2016-003835-39 | A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry ... | 2019-04-13 | due-trials |
| Reported results | 2016-004661-23 | An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older with Severe Eosinophilic Asthma | 2018-02-22 | due-trials |
| Trial is outside EEC, and reported results | 2017-002060-40 | A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in ... | bad-data | |
| Reported results | 2017-002441-30 | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migrai... | 2019-05-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002976-24 | A Well-Controlled, Fixed-Dose Study of TEV 50717 (Deutetrabenazine) for the Treatment of Tics Associated with Tourette Syndrome | 2019-12-05 | bad-data |
| Trial is outside EEC, and reported results | 2018-000734-35 | A Single-Dose, Open-Label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous administration of Fremanezumab in Pediatric Migraine Patients (6 to 11 Years of Age Incl... | bad-data | |
| Reported results | 2018-001619-65 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous U... | 2020-12-03 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-003742-17 | A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents | 2022-07-21 | bad-data |
| Reported results | 2019-000063-24 | A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients... | 2021-12-02 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-001807-19 | An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP) | 2023-02-14 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-001989-15 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Mi... | 2022-08-31 | bad-data |
| Ongoing | 2019-002053-33 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the... | not-yet-due | |
| Completed, reported early | 2019-002055-42 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the... | 2024-03-13 | not-yet-due |
| Other | 2019-002056-16 | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic ... | not-yet-due | |
| Reported results | 2020-001927-15 | A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults with T2-low/non-T2 Severe Uncontrolled Asthma | 2022-01-17 | due-trials |
| Not reported | 2020-005548-48 | A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (PROLIA®) in Patients with Postmenopausal Osteoporosis | 2023-06-19 | due-trials |
| Completed, report not yet due | 2021-001796-17 | A Multinational, Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV 45779 Compared to Omalizumab ... | 2024-04-05 | not-yet-due |
| Reported results Terminated | 2021-003951-41 | CONNected Electronic Inhalers Asthma Control Trial 3 (“CONNECT 3”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus the B... | 2023-06-29 | due-trials |
| Other | 2021-006881-19 | A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative... | not-yet-due | |
| Ongoing | 2022-001865-11 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanza... | not-yet-due | |
| Ongoing | 2022-002593-89 | A 24-Week, Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy Safety, and Tolerability of TEV-48574 in Adult Patients with Moderate to Severe Ulcerativ... | not-yet-due |